このエントリーをはてなブックマークに追加
ID 52928
Sort Key
1
タイトル(別表記)
The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki Prize)
フルテキストURL
Thumnail 126_187.pdf 492 KB
著者
山本 寛斉 岡山大学大学院医歯薬学総合研究科 呼吸器・乳腺内分泌外科学
抄録
受賞対象論文: Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, Matsuo K, Kiura K, Miyoshi S, Matsuda F, Toyooka S:Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst (2014) 106, djt338
備考
平成25年度岡山医学会賞紹介記事 (The 2013 Okayama Medical Association Award)
出版物タイトル
岡山医学会雑誌
発行日
2014-12-01
126巻
3号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
187
終了ページ
190
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
OAI-PMH Set
岡山大学
言語
Japanese
著作権者
Copyright (c) 2014 岡山医学会
論文のバージョン
publisher
査読
有り
DOI
NAID
Eprints Journal Name
joma
参考文献
1) Heinen CD : Genotype to phenotype : analyzing the effects of inherited mutations in colorectal cancer families. Mutat Res (2010) 693, 32-45.
2) Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X : Common BRCA1 and BRCA2 mutations in breast cancer families : a meta-analysis from systematic review. Mol Biol Rep (2012) 39, 2109-2118.
3) Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, et al. : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 97, 339-346.
4) Pao W, Girard N : New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 12, 175-180.
5) Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA : Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 37, 1315-1316.
6) Ikeda K, Nomori H, Mori T, Sasaki J, Kobayashi T : Novel germline mutation : EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg (2008) 85, 1430-1432.
7) Ohtsuka K, Ohnishi H, Kurai D, Matsushima S, Morishita Y, Shinonaga M, Goto H, Watanabe T : Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol (2011) 29, e191-192.
8) van Noesel J, van der Ven WH, van Os TA, Kunst PW, Weegenaar J, Reinten RJ, Kancha RK, Duyster J, van Noesel CJ : Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol (2013) 31, e161-164.
9) Yamaguchi T, Hosomichi K, Narita A, Shirota T, Tomoyasu Y, Maki K, Inoue I : Exome resequencing combined with linkage analysis identifies novel PTH1R variants in primary failure of tooth eruption in Japanese. J Bone Miner Res (2011) 26, 1655-1661.
10) Kumar P, Henikoff S, Ng PC : Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 4, 1073-1081.
11) Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR : A method and server for predicting damaging missense mutations. Nat Methods (2010) 7, 248-249.
12) Chun S, Fay JC : Identification of deleterious mutations within three human genomes. Genome Res (2009) 19, 1553-1561.
13) Schwarz JM, Rodelsperger C, Schuelke M, Seelow D : MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods (2010) 7, 575-576.
14) Siepel A, Pollard KS, Haussler D : New methods for detecting lineage-specific selection ; in Research in Computational Molecular Biology. Apostolico A, Guerra C, Istrail S, Pevzner PA, Waterman M (eds), Springer Berlin Heidelberg, Berlin (2006) pp190-205.
15) Martin V, Cappuzzo F, Mazzucchelli L, Frattini M : HER2 in solid tumors : more than 10 years under the microscope ; where are we now? Future Oncol (2014) 10, 1469-1486.
16) Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, et al. : Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 65, 1642-1646.
17) Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, et al. : Lung cancer : intragenic ERBB2 kinase mutations in tumours. Nature (2004) 431, 525-526.
18) Baselga J, Swain SM : Novel anticancer targets : revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 9, 463-475.
19) Engelman JA : Targeting PI3K signalling in cancer : opportunities, challenges and limitations. Nat Rev Cancer (2009) 9, 550-562.
20) Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P : Mitogen-activated protein kinase activation in lung adenocarcinoma : a comparative study between ever smokers and never smokers. Clin Cancer Res (2008) 14, 4096-4102.
21) Planchard D, Camara-Clayette V, Dorvault N, Soria JC, Fouret P : p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer (2012) 118, 5015-5025.
22) Cirulli ET, Goldstein DB : Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 11, 415-425.